Hyman Muss1, Javier Cortes, Linda T Vahdat, Fatima Cardoso, Chris Twelves, Jantien Wanders, Corina E Dutcus, Jay Yang, Seth Seegobin, Joyce O'Shaughnessy. 1. University of North Carolina Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, USA; Vall d'Hebron University Hospital and Vall d'Hebron Institute of Oncology, Barcelona, Spain; Weill Cornell Medical College, New York, New York, USA; Jules Bordet Institute, Brussels, Belgium; University of Leeds and St James's Institute of Oncology, Leeds, UK; Formerly of Eisai Ltd, Hatfield, UK; Eisai Inc., Woodcliff Lake, New Jersey, USA; NJS Associates Company, Somerset, New Jersey USA; Baylor-Charles A. Sammons Cancer Center, Texas Oncology, and US Oncology, Dallas, Texas, USA.
Abstract
PURPOSE: Following the demonstrated efficacy and safety of eribulin mesylate in heavily pretreated patients with metastatic breast cancer, an exploratory analysis was performed to investigate the effect of age in these patients. METHODS: Data were pooled from two single-arm phase II studies and one open-label randomized phase III study in which patients received eribulin mesylate at 1.4 mg/m(2) as 2- to 5-minute intravenous infusions on days 1 and 8 of a 21-day cycle. The effect of age on median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), clinical benefit rate (CBR), and incidence of adverse events (AEs) was calculated for four age groups (<50 years, 50-59 years, 60-69 years, ≥ 70 years). RESULTS. Overall, 827 patients were included in the analysis (<50 years, n = 253; 50-59 years, n = 289; 60-69 years, n = 206; ≥ 70 years, n = 79). Age had no significant impact on OS (11.8 months, 12.3 months, 11.7 months, and 12.5 months, respectively; p = .82), PFS (3.5 months, 2.9 months, 3.8 months, and 4.0 months, respectively; p = .42), ORR (12.7%, 12.5%, 6.3%, and 10.1%, respectively), or CBR (20.2%, 20.8%, 20.4%, and 21.5%, respectively). Although some AEs had higher incidence in either the youngest or the oldest subgroup, there was no overall effect of age on the incidence of AEs (including neuropathy, neutropenia, and leukopenia). CONCLUSION:Eribulin monotherapy in these selected older patients with good baseline performance status led to OS, PFS, ORR, CBR, and tolerability similar to those of younger patients with metastatic breast cancer. The benefits and risks of eribulin appear to be similar across age groups.
RCT Entities:
PURPOSE: Following the demonstrated efficacy and safety of eribulin mesylate in heavily pretreated patients with metastatic breast cancer, an exploratory analysis was performed to investigate the effect of age in these patients. METHODS: Data were pooled from two single-arm phase II studies and one open-label randomized phase III study in which patients received eribulin mesylate at 1.4 mg/m(2) as 2- to 5-minute intravenous infusions on days 1 and 8 of a 21-day cycle. The effect of age on median overall survival (OS), progression-free survival (PFS), overall response rate (ORR), clinical benefit rate (CBR), and incidence of adverse events (AEs) was calculated for four age groups (<50 years, 50-59 years, 60-69 years, ≥ 70 years). RESULTS. Overall, 827 patients were included in the analysis (<50 years, n = 253; 50-59 years, n = 289; 60-69 years, n = 206; ≥ 70 years, n = 79). Age had no significant impact on OS (11.8 months, 12.3 months, 11.7 months, and 12.5 months, respectively; p = .82), PFS (3.5 months, 2.9 months, 3.8 months, and 4.0 months, respectively; p = .42), ORR (12.7%, 12.5%, 6.3%, and 10.1%, respectively), or CBR (20.2%, 20.8%, 20.4%, and 21.5%, respectively). Although some AEs had higher incidence in either the youngest or the oldest subgroup, there was no overall effect of age on the incidence of AEs (including neuropathy, neutropenia, and leukopenia). CONCLUSION:Eribulin monotherapy in these selected older patients with good baseline performance status led to OS, PFS, ORR, CBR, and tolerability similar to those of younger patients with metastatic breast cancer. The benefits and risks of eribulin appear to be similar across age groups.
Entities:
Keywords:
Age; Chemotherapy; Eribulin mesylate; Metastatic breast cancer
Authors: Laura Biganzoli; Robert Coleman; Alessandro Minisini; Anne Hamilton; Matti Aapro; Patrick Therasse; Giuseppe Mottino; Jan Bogaerts; Martine Piccart Journal: Crit Rev Oncol Hematol Date: 2006-11-20 Impact factor: 6.312
Authors: M J Towle; K A Salvato; J Budrow; B F Wels; G Kuznetsov; K K Aalfs; S Welsh; W Zheng; B M Seletsky; M H Palme; G J Habgood; L A Singer; L V Dipietro; Y Wang; J J Chen; D A Quincy; A Davis; K Yoshimatsu; Y Kishi; M J Yu; B A Littlefield Journal: Cancer Res Date: 2001-02-01 Impact factor: 12.701
Authors: S M Lichtman; A Hurria; C T Cirrincione; A D Seidman; E Winer; C Hudis; H J Cohen; H B Muss Journal: Ann Oncol Date: 2011-06-21 Impact factor: 32.976
Authors: Linda T Vahdat; Brian Pruitt; Carol J Fabian; Ragene R Rivera; David A Smith; Elizabeth Tan-Chiu; Jonathan Wright; Antoinette R Tan; Noshir A Dacosta; Ellen Chuang; John Smith; Joyce O'Shaughnessy; Dale E Shuster; Nicole L Meneses; Kumari Chandrawansa; Fang Fang; Patricia E Cole; Simon Ashworth; Joanne L Blum Journal: J Clin Oncol Date: 2009-04-06 Impact factor: 44.544
Authors: Tatiana Okouneva; Olga Azarenko; Leslie Wilson; Bruce A Littlefield; Mary Ann Jordan Journal: Mol Cancer Ther Date: 2008-07 Impact factor: 6.261
Authors: R Largillier; J-M Ferrero; J Doyen; J Barriere; M Namer; V Mari; A Courdi; J M Hannoun-Levi; F Ettore; I Birtwisle-Peyrottes; C Balu-Maestro; P Y Marcy; I Raoust; M Lallement; E Chamorey Journal: Ann Oncol Date: 2008-07-17 Impact factor: 32.976
Authors: Fatima Cardoso; Philippe L Bedard; Eric P Winer; Olivia Pagani; Elzbieta Senkus-Konefka; Lesley J Fallowfield; Stella Kyriakides; Alberto Costa; Tanja Cufer; Kathy S Albain Journal: J Natl Cancer Inst Date: 2009-08-05 Impact factor: 13.506
Authors: Jared C Foster; Jennifer G Le-Rademacher; Josephine L Feliciano; Ajeet Gajra; Drew K Seisler; Ronald DeMatteo; Jacqueline M Lafky; Arti Hurria; Hyman B Muss; Harvey J Cohen; Aminah Jatoi Journal: Cancer Date: 2017-07-12 Impact factor: 6.860
Authors: Ajeet Gajra; Tyler J Zemla; Aminah Jatoi; Josephine L Feliciano; Melisa L Wong; Hongbin Chen; Ronald Maggiore; Ryan P McMurray; Arti Hurria; Hyman B Muss; Harvey J Cohen; Jacqueline Lafky; Martin J Edelman; Rogerio Lilenbaum; Jennifer G Le-Rademacher Journal: J Thorac Oncol Date: 2018-03-30 Impact factor: 15.609
Authors: Ornella Garrone; Filippo Montemurro; Chiara Saggia; Nicla La Verde; Anna Maria Vandone; Mario Airoldi; Enrico De Conciliis; Michela Donadio; Francesco Lucio; Maria Antonia Polimeni; Maria Vittoria Oletti; Alice Giacobino; Marco Carlo Merlano Journal: Springerplus Date: 2016-01-21